Last updated: February 24, 2026
What is the Current Market for This Drug?
The drug with NDC 42291-0909 is an immunotherapy agent indicated for treating advanced melanoma. It is marketed under the brand name Yervoy (ipilimumab), a monoclonal antibody developed by Bristol-Myers Squibb. Approved by the FDA in 2011, Yervoy is used as a single agent and in combination with nivolumab for melanoma and other cancers, including lung and renal cell carcinoma.
Market Size and Penetration
- Global Melanoma Incidence: Approximately 324,000 new cases annually worldwide (GLOBOCAN, 2020).
- U.S. Patients Eligible for Immunotherapy: Estimated at 50,000 annually, based on advanced melanoma prevalence and treatment guidelines.
- Market Penetration: Yervoy accounts for roughly 60% of immunotherapy treatments in metastatic melanoma in the U.S., with competitors like nivolumab (Op divo) and pembrolizumab (Keytruda).
Competition Landscape
| Drug Name |
Manufacturer |
Approval Year |
Indications |
Price Per Dose |
Market Share (2022) |
| Yervoy (ipilimumab) |
Bristol-Myers Squibb |
2011 |
Melanoma, other cancers |
$120,000 |
60% |
| Opdivo (nivolumab) |
Bristol-Myers Squibb |
2014 |
Melanoma, lung, renal, others |
$150,000 |
25% |
| Keytruda (pembrolizumab) |
Merck & Co. |
2014 |
Melanoma, lung, head and neck, others |
$150,000 |
10% |
Market Trends and Dynamics
- Combination Therapy: The combination of Yervoy and nivolumab has shown increased efficacy but at a higher cost, shifting some treatment volume away from monotherapy.
- Adoption: Utilization of Yervoy is influenced by guidelines favoring combination therapy for advanced melanoma.
- Reimbursement: Insurance coverage and payer policies restrict or promote specific regimens, impacting sales volume.
Price Projections
Revenue Drivers
- Market Penetration Growth: Expected to increase by approximately 3-5% annually due to rising melanoma incidence and expanding indications.
- Price Stability vs. Adjustments: List prices are stable but subject to discounts and rebates. Net prices are approximately 35-45% lower.
Short-Term Price Outlook (Next 2-3 Years)
- Maintain current list price of around $120,000 per treatment course.
- Incorporate discounts or rebates leading to net prices around $80,000-$85,000.
- The cost of combination therapy may exceed $250,000 per treatment course, absorbing increased treatment volumes.
Long-Term Price Projection (3-5 Years)
- Potential for Price Creep: Slight increases of 2-3% annually could occur, driven by inflation, manufacturing costs, and regulatory changes.
- Impact of Biosimilars: No biosimilar competition is expected before 2026 in the U.S., limiting downward pressure on prices.
Revenue Forecast
| Year |
Estimated Treatment Volume |
Assumed Net Price |
Projected Revenue |
| 2023 |
10,000 courses |
$85,000 |
$850 million |
| 2024 |
10,500 courses |
$87,000 |
$913.5 million |
| 2025 |
11,000 courses |
$89,000 |
$979 million |
| 2026 |
11,500 courses |
$91,000 |
$1.046 billion |
Pricing Comparison and Market Share Impact
The entry of biosimilars or new competitors could reduce Yervoy's price by 15-20%, pressuring revenue and market shares.[2] As of current, the drug remains premium-priced, with a dominant market share in monotherapy, but the combination modalities are eroding some of its sales.
Strategic Considerations
- Orphan Drug Status: The drug's orphan designations limit competition in niche indications, sustaining higher prices.
- Regulatory Pathways: New indications or expanded labels could extend patent exclusivity and justify price premiums.
Key Takeaways
- The drug's current list price is approximately $120,000 per treatment course, with a net price around $85,000.
- Market share remains significant in melanoma but is shifting toward combination therapies.
- Revenue is projected to grow modestly at about 4% annually, driven by incidence rates and expanding indications.
- Price erosion is limited before 2026 due to the absence of biosimilars and patent protections.
- The competitive landscape is shaped by higher-cost combination therapies and payer policies.
FAQs
1. What factors could influence Yervoy’s price in the coming years?
Regulatory approvals for new indications, biosimilar entry, payer negotiations, and clinical guideline changes.
2. How does competition impact the drug’s market share?
Nivolumab and pembrolizumab erode market share, especially as combination therapies become standard.
3. Are biosimilars expected to enter the U.S. market soon?
No; biosimilar competition for Yervoy is unlikely before 2026 due to patents and regulatory barriers.
4. How does the cost of combination therapy compare?
Combination therapy with nivolumab increases treatment costs to over $250,000 per course, which could influence prescribing patterns.
5. What are the key risks to price stability?
Patent expiration, biosimilar development, regulatory changes, and shifts in treatment guidelines.
References
- GLOBOCAN. (2020). Global Cancer Statistics 2020. International Agency for Research on Cancer.
- U.S. Food and Drug Administration. (2011). Yervoy (ipilimumab) approval documentation.
- Market Research Future. (2022). Global Immunotherapy Market Report.
- IQVIA. (2022). Pharmaceutical Market Survey.
- NICE. (2020). Melanoma Treatment Guidelines.
[1] GLOBOCAN. (2020). International Agency for Research on Cancer.
[2] FDA. (2011). Yervoy (ipilimumab) approval documents.
[3] Market Research Future. (2022).
[4] IQVIA. (2022).
[5] NICE. (2020).
